Document is current

Article History

Received: 14 July 2024

Accepted: 20 March 2025

First Online: 2 April 2025

Declarations

:

: M.Zapater-Fajarí; I.Crespo-Sanmiguel; N.Cedres; T. Rydberg Sterner; L.Rydén, S.Scuiu; M.Waern, A. Zettergren; V.Hidalgo; A. Salvador; E. Westman and I. Skoog declare no competing interests; H. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work); K.Blennow has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper; S.Kern has served at scientific advisory boards and / or as consultant for Geras Solutions and Biogen and Bioarctic and D.Ferreira consults for BioArctic and has received honoraria from Esteve.

: The H70 study was approved by the Regional Ethical Review Board in Gothenburg (Approval Numbers: 869-13, T076-14, T166-14, 976-13, 127-14, T936-15, 006-14, T703-14, 006-14, T201-17, T915-14, 959-15, T139-15), and by the Radiation Protection Committee (Approval Number: 13-64) in concordance with the 1964 Helsinki declaration and its later amendment. Informed consent was obtained from all participants or their relatives if the participant was unable to provide informed consent.